Press Release July 16, 2015

Goodwin Advises AMRI in $174 Million Acquisition of Gadea Pharmaceutical Group

A team of Goodwin Procter attorneys recently advised AMRI in its $174 million acquisition of Gadea Pharmaceutical Group. The transaction included the purchase of all outstanding shares of Gadea, with 2.2 million shares of common stock issued to Gadea’s owners and the balance of the purchase price paid in cash and through the assumption of debt. Additional information regarding the transaction is available in AMRI’s press release.

Albany Molecular Research Inc. (AMRI), based in Albany, N.Y., is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, AMRI’s key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing. The company is traded on the Nasdaq exchange under ticker “AMRI.”

Gadea Pharmaceutical Group is a Spanish group of affiliated companies dedicated to the technical development and production of API and finished drug forms. Gadea's Crystal Pharma business unit is recognized as a leader in large scale commercial API production, specializing in steroids, high potency hormones and sterile steroids (by filtration). The privately-held company is based in Vallodiolid, Spain.

The Goodwin team advising AMRI was led by partners Stuart Cable and Danielle Lauzon and associates Samuel Ntonme and Payson Lyman (corporate), with key advice from partners Jennifer Bralower (debt finance), Rich Matheny (export/import) and Janet Andolina (tax). Gomez-Acebo & Pombo Abogados, S.L.P. also advised AMRI.